In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.
© 2025. The Author(s).